Compare Novavax Inc (NVAX) vs VICI Properties Inc (VICI) Price & Performance

Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.

The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.

VICI Properties trades at $22.83, up 0.84% today, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 8.83, net income margin of 67.5%, and robust cash flow from operations of $2.51B in 2025. Recent news highlights dividend coverage strength despite stock price declines, and the company expanded its tenant base with a new lease for Century Mile and Century Downs.

The outlook is mixed: analyst consensus is strongly bullish with a $28.90 price target, but risks include tenant concentration and rising Treasury yields. The stock offers value with a low P/E and high dividend yield, but investors should weigh the bearish technicals and macroeconomic pressures against the solid fundamental performance.